Androgen receptor profiling predicts prostate cancer outcome.
Bottom Line: Biomarkers for outcome prediction are urgently needed, so that high-risk patients could be monitored more closely postoperatively.These differential androgen receptor/chromatin interactions dictated expression of a distinct gene signature with strong prognostic potential.By combining existing technologies, we propose a novel pipeline for biomarker discovery that is easily implementable in other fields of oncology.
Affiliation: Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.Show MeSH
Related in: MedlinePlus
Mentions: Since AR and its interactors were enriched at FAIRE-seq regions (Fig2G), we next performed AR ChIP-seq on five primary and three treatment-resistant tumor specimens (Fig3A). The number of reads and AR binding events is shown in Appendix Table S4. The total number of identified AR binding events greatly varied between the tumor samples (Appendix Table S4), which is consistent with previous nuclear receptor ChIP-seq in prostate and breast tumor samples (Ross-Innes et al, 2012; Jansen et al, 2013; Sharma et al, 2013). Specifically, our AR binding sites varied from 238 up to 17,511 per tumor sample, which is in the same order of magnitude as in Sharma et al, with 300–8,500 per tumor sample (Sharma et al, 2013).
Affiliation: Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.